{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:29:04Z","timestamp":1787887744542,"version":"build-2784847793"},"reference-count":42,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wuhan Applied Basic Research Frontier Program","award":["2019020701011448 (to X.C.)"],"award-info":[{"award-number":["2019020701011448 (to X.C.)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adenoviruses can cause infections in people of all ages at all seasons of the year. Adenovirus infections cause mild to severe illnesses. Children, immunocompromised patients, or those with existing respiratory or cardiac disease are at higher risk. Unfortunately, there are no commercial drugs or vaccines available on the market for adenovirus infections. Therefore, there is an urgent need to discover new antiviral drugs or drug targets for adenovirus infections. To identify potential antiviral agents for adenovirus infections, we screened a drug library containing 2138 compounds, most of which are drugs with known targets and past phase I clinical trials. On a cell-based assay, we identified 131 hits that inhibit adenoviruses type 3 and 5. A secondary screen confirmed the antiviral effects of 59 inhibitors that inhibit the replication of adenoviruses type 3 or 5. Most of the inhibitors target heat shock protein, protein tyrosine kinase, the mTOR signaling pathway, and other host factors, suggesting that these host factors may be essential for replicating adenoviruses. Through this study, the newly identified adenovirus inhibitors may provide a start point for developing new antiviral drugs to treat adenovirus infections. Further validation of the identified drug targets can help the development of new therapeutics against adenovirus infections.<\/jats:p>","DOI":"10.3390\/v14050959","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:21:25Z","timestamp":1651652485000},"page":"959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Identification of Inhibitors and Drug Targets for Human Adenovirus Infections"],"prefix":"10.3390","volume":"14","author":[{"given":"Minli","family":"Liu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China"},{"name":"College of Life Sciences, University of the Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lefang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Cao","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-2895","authenticated-orcid":false,"given":"Jianguo","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-1145","authenticated-orcid":false,"given":"Xulin","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China"},{"name":"College of Life Sciences, University of the Chinese Academy of Sciences, Beijing 100049, China"},{"name":"Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou 510632, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"ref_1","unstructured":"Shieh, W.J. Human adenovirus infections in pediatric population\u2014An update on clinico-pathologic correlation. Biomed. J.  2021, S2319-4170(21)00109-8. in press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100432","DOI":"10.1016\/j.dmpk.2021.100432","article-title":"Adenovirus vector-based vaccine for infectious diseases","volume":"42","author":"Sakurai","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.coviro.2021.03.006","article-title":"Adenovirus\u2014A blueprint for gene delivery","volume":"48","author":"Greber","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5\u2013based Constructs","volume":"24","author":"Papp","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14656566.2017.1322063","article-title":"Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients","volume":"18","author":"Grim","year":"2017","journal-title":"Expert Opin Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/protein\/4.7.711","article-title":"The role of heat-shock and chaperone proteins in protein folding: Possible molecular mechanisms","volume":"4","author":"Hubbard","year":"1991","journal-title":"Protein Eng."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Poulain, P., Gelly, J.C., and Flatters, D. (2010). Detection and architecture of small heat shock protein monomers. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009990"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1242\/jcs.01373","article-title":"Hsp70 dynamics in vivo: Effect of heat shock and protein aggregation","volume":"117","author":"Zeng","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/bioinformatics\/bts520","article-title":"HSPIR: A manually annotated heat shock protein information resource","volume":"28","author":"NS","year":"2012","journal-title":"Bioinformatics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ab.2013.05.024","article-title":"iHSP-PseRAAAC: Identifying the heat shock protein families using pseudo reduced amino acid alphabet composition","volume":"442","author":"Feng","year":"2013","journal-title":"Anal. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-030-40204-4_9","article-title":"The Right Tool for the Job: An Overview of Hsp90 Inhibitors","volume":"1243","author":"Koren","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcancer.2018.01.006","article-title":"P21 activated kinase signaling in cancer","volume":"54","author":"Rane","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543776.2021.1944100","article-title":"Drug discovery targeting p21-activated kinase 4 (PAK4): A patent review","volume":"31","author":"Wang","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/15384101.2021.1897271","article-title":"Regulation of DNA duplication by the mTOR signaling pathway","volume":"20","author":"He","year":"2021","journal-title":"Cell Cycle"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_21","first-page":"332","article-title":"The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment","volume":"17","author":"Maiese","year":"2020","journal-title":"Curr. Neurovasc. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kovacs, T., Zakany, F., and Nagy, P. (2022). It Takes More than Two to Tango: Complex, Hierarchal, and Membrane-Modulated Interactions in the Regulation of Receptor Tyrosine Kinases. Cancers, 14.","DOI":"10.3390\/cancers14040944"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Saha, T., and Gil-Henn, H. (2021). Invadopodia, a Kingdom of Non-Receptor Tyrosine Kinases. Cells, 10.","DOI":"10.3390\/cells10082037"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.1158\/0008-5472.CAN-10-3001","article-title":"Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines","volume":"70","author":"Payton","year":"2010","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3389\/fmicb.2017.01171","article-title":"CRM1 Inhibitors for Antiviral Therapy","volume":"8","author":"Mathew","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Widman, D.G., Gornisiewicz, S., Shacham, S., and Tamir, S. (2018). In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals. PLoS ONE, 13.","DOI":"10.1101\/351825"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/1348-0421.12828","article-title":"Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2","volume":"64","author":"Kato","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hahn, F., Wangen, C., Hage, S., Peter, A.S., Dobler, G., Hurst, B., Julander, J., Fuchs, J., Ruzsics, Z., and Uberla, K. (2020). IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Viruses, 12.","DOI":"10.3390\/v12121394"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dalidowska, I., Gazi, O., Sulejczak, D., Przybylski, M., and Bieganowski, P. (2021). Heat Shock Protein 90 Chaperones E1A Early Protein of Adenovirus 5 and Is Essential for Replication of the Virus. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042020"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/10428194.2016.1213823","article-title":"Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood","volume":"58","author":"Shatzer","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e01142-19","DOI":"10.1128\/JVI.01142-19","article-title":"Heat Shock Protein 90 Ensures the Integrity of Rubella Virus p150 Protein and Supports Viral Replication","volume":"93","author":"Sakata","year":"2019","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00280-014-2584-8","article-title":"Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation","volume":"74","author":"Patel","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2010.04.015","article-title":"Inhibition of heat-shock protein 90 reduces Ebola virus replication","volume":"87","author":"Smith","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1080\/22221751.2020.1850183","article-title":"Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target","volume":"9","author":"Li","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41467-021-22166-4","article-title":"SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition","volume":"12","author":"Mullen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"108940","DOI":"10.1016\/j.celrep.2021.108940","article-title":"Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication","volume":"35","author":"Garcia","year":"2021","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","article-title":"Repurposing of Kinase Inhibitors for Treatment of COVID-19","volume":"37","author":"Weisberg","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbamcr.2011.11.007","article-title":"Broad action of Hsp90 as a host chaperone required for viral replication","volume":"1823","author":"Geller","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1128\/JVI.06275-11","article-title":"CRM1-dependent transport supports cytoplasmic accumulation of adenoviral early transcripts","volume":"86","author":"Schmid","year":"2012","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:06:02Z","timestamp":1760137562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["v14050959"],"URL":"https:\/\/doi.org\/10.3390\/v14050959","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]}}}